Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy

[1]  Joshua M. Korn,et al.  Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2008, Nature.

[2]  J. Inazawa,et al.  Frequent silencing of a putative tumor suppressor gene melatonin receptor 1 A (MTNR1A) in oral squamous‐cell carcinoma , 2008, Cancer science.

[3]  E. Lander,et al.  Assessing the significance of chromosomal aberrations in cancer: Methodology and application to glioma , 2007, Proceedings of the National Academy of Sciences.

[4]  S. Ishikawa,et al.  Constitutive activation of c‐Met is correlated with c‐Met overexpression and dependent on cell–matrix adhesion in lung adenocarcinoma cell lines , 2007, Cancer science.

[5]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[6]  G. Mills,et al.  Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells , 2006, Molecular Cancer Therapeutics.

[7]  C. Rhee,et al.  Ionizing radiation enhances matrix metalloproteinase-2 secretion and invasion of glioma cells through Src/epidermal growth factor receptor-mediated p38/Akt and phosphatidylinositol 3-kinase/Akt signaling pathways. , 2006, Cancer research.

[8]  Angelo L. Vescovi,et al.  Brain tumour stem cells , 2006, Nature Reviews Cancer.

[9]  M. Nguyen,et al.  Reduced Glioma Infiltration in Src-deficient Mice , 2006, Journal of Neuro-Oncology.

[10]  Gayatry Mohapatra,et al.  Amplification of MET may identify a subset of cancers with extreme sensitivity to the selective tyrosine kinase inhibitor PHA-665752 , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[11]  William Pao,et al.  Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[12]  J. Rush,et al.  Immunoaffinity profiling of tyrosine phosphorylation in cancer cells , 2005, Nature Biotechnology.

[13]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[14]  D. Kaplan,et al.  SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions. , 2004, Molecular cancer research : MCR.

[15]  J. Parsons,et al.  Src family kinases, key regulators of signal transduction , 2004, Oncogene.

[16]  Ping Chen,et al.  Overriding Imatinib Resistance with a Novel ABL Kinase Inhibitor , 2004, Science.

[17]  Andrew L Kung,et al.  A small-molecule antagonist of CXCR4 inhibits intracranial growth of primary brain tumors , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[18]  P. Mishra,et al.  Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. , 2003, Cancer research.

[19]  C. Desbois-Mouthon,et al.  Dysregulation of glycogen synthase kinase-3beta signaling in hepatocellular carcinoma cells. , 2002, Hepatology.

[20]  C. Desbois-Mouthon,et al.  Dysregulation of glycogen synthase kinase‐3β signaling in hepatocellular carcinoma cells , 2002 .

[21]  Alvan R. Feinstein,et al.  Principles of Medical Statistics , 2001 .

[22]  T. Jacks,et al.  STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications , 2001, Oncogene.

[23]  P. N. Rao,et al.  Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification , 2001, Science.

[24]  M. Makuuchi,et al.  Deletion of the carboxyl-terminal exons of K-sam/FGFR2 by short homology-mediated recombination, generating preferential expression of specific messenger RNAs. , 1999, Cancer research.

[25]  W. Gullick,et al.  NDF/heregulin stimulates the phosphorylation of Her3/erbB3 , 1994, FEBS letters.

[26]  C. James,et al.  Identical splicing of aberrant epidermal growth factor receptor transcripts from amplified rearranged genes in human glioblastomas. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[27]  Kees Stam,et al.  Structural organization of the bcr gene and its role in the Ph′ translocation , 1985, Nature.

[28]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[29]  J. Dumanski,et al.  Deregulation of the platelet-derived growth factor β-chain gene via fusion with collagen gene COL1A1 in dermatof ibrosarcoma protuberans and giant-cell fibroblastoma , 1997, Nature Genetics.

[30]  B. Efron.  Nonparametric standard errors and confidence intervals , 1981 .